Group wants Ortho patch withdrawn

We've all heard the safety warnings about the Ortho-Evra birth control patch and its link to life-threatening blood clots. The FDA has updated the Johnson & Johnson drug's labeling three times to notify about the risks, including once early this year. And demand for the patch has dropped to 2.7 million prescriptions in 2007 from 9.9 million in 2004. But Public Citizen isn't satisfied. It wants the patch taken off the market completely.

In a petition to the FDA, the consumer advocacy group argued that the patch doesn't offer better contraception to outweigh the extra risk of blood clots. And it alleges that plaintiff's lawsuits have uncovered two unpublished studies by J&J researchers, who found higher estrogen exposure from the patch even before it won agency approval in 2001.

Johnson & Johnson defended its product, saying it's safe and effective when used according to its labeling. The agency had no comment because it hadn't yet reviewed the petition.

- read the New York Times article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.